Myriad Genetics, Inc. (NASDAQ:MYGN) posted its quarterly earnings results on Tuesday. The company reported $0.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.04, reports. The company had revenue of $200.50 million for the quarter, compared to analysts’ expectations of $193.71 million. Myriad Genetics had a return on equity of 10.53% and a net margin of 4.26%. The firm’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.36 earnings per share. Myriad Genetics updated its Q1 guidance to $0.19-0.21 EPS and its FY18 guidance to $1.00-1.05 EPS.

Shares of Myriad Genetics (NASDAQ:MYGN) traded up 1.35% during mid-day trading on Tuesday, reaching $25.55. 1,863,830 shares of the company’s stock traded hands. The company’s 50 day moving average is $24.97 and its 200-day moving average is $20.53. Myriad Genetics has a 52 week low of $15.15 and a 52 week high of $31.49. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of 54.59 and a beta of 0.31.

Several research analysts have issued reports on the company. BidaskClub cut Myriad Genetics from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $22.00 price target on shares of Myriad Genetics in a report on Friday, July 14th. Cowen and Company reaffirmed a “hold” rating and issued a $25.00 price target on shares of Myriad Genetics in a report on Friday, July 14th. Deutsche Bank AG upped their price target on Myriad Genetics from $15.00 to $20.00 and gave the company a “sell” rating in a report on Monday, May 8th. Finally, Zacks Investment Research raised Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 price target on the stock in a report on Monday, July 17th. Five analysts have rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $21.77.

WARNING: “Myriad Genetics, Inc. (NASDAQ:MYGN) Releases Quarterly Earnings Results” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Earnings History for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with's FREE daily email newsletter.